Prudence A Francis

Prudence A Francis

UNVERIFIED PROFILE

Are you Prudence A Francis?   Register this Author

Register author
Prudence A Francis

Prudence A Francis

Publications by authors named "Prudence A Francis"

Are you Prudence A Francis?   Register this Author

44Publications

1869Reads

40Profile Views

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.

J Clin Oncol 2019 Oct 16:JCO1801967. Epub 2019 Oct 16.

International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01967DOI Listing
October 2019

Implementation of a Multidisciplinary Model of Care for Women With Metastatic Breast Cancer: Challenges and Lessons Learned.

Clin Breast Cancer 2019 Apr 21;19(2):e327-e336. Epub 2018 Dec 21.

Department of Nursing, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.014DOI Listing
April 2019

Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.

J Clin Oncol 2019 Apr 27;37(11):862-866. Epub 2019 Feb 27.

5 Geneva University Hospitals, Lugano Viganello, Switzerland and Institute of Oncology of Southern Switzerland, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.02433
Publisher Site
http://dx.doi.org/10.1200/JCO.18.02433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455715PMC
April 2019

In Reply to Belkacemi and Tsoutsou.

Int J Radiat Oncol Biol Phys 2018 10;102(2):467-468

Peter MacCallum Cancer Centre, Melbourne, Australia; St Vincent's Hospital, University of Melbourne, Melbourne, Australia; Breast Cancer Trials Australia & New Zealand, University of Newcastle, Newcastle, Australia; International Breast Cancer Study Group, Bern, Switzerland.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016183096
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2018.06.010DOI Listing
October 2018

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

N Engl J Med 2018 Jul 4;379(2):122-137. Epub 2018 Jun 4.

From the Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Newcastle, NSW (P.A.F.), and the University of Sydney, Sydney (A.S.C.) - all in Australia; the Institute of Oncology of Southern Switzerland, Ospedale San Giovanni, Bellinzona (O.P.), Breast Cancer St. Gallen, St. Gallen (T.R.), and the International Breast Cancer Study Group Coordinating Center (R.M., M.R.-P., B.R., A.S.C.), University Hospital Inselspital (M.R.-P.), Bern - all in Switzerland; the University of Chicago Medical Center, Chicago (G.F.F.); the University of Calgary, Calgary, AB, Canada (B.A.W.); the Division of Medical Senology, European Institute of Oncology (M.C.), and the European Institute of Oncology and International Breast Cancer Study Group (A.G.), Milan, Ospedale Papa Giovanni XXIII, Bergamo (C.T.), Azienda Socio Sanitaria Territoriale Sette Laghi-Ospedale di Circolo and Fondazione Macchi, Varese (G.P.), Medical Oncology and Cancer Prevention, IRCCS, National Cancer Institute, Aviano (F.P., S.S.), the Department of Medicine, School of Medical Oncology, University of Udine, Udine (F.P.), Salvatore Maugeri Foundation, Pavia (L.P.), and the Hospital of Prato-Azienda Unità Sanitaria Locale Toscana Centro, Prato (A.D.L.) - all in Italy; the National Institute of Oncology, Budapest, Hungary (I.L.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.); University Hospital 12 de Octubre, Madrid (E.C.), Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (M.B.), and Instituto Valenciano de Oncologia, Valencia (M.A.C.) - all in Spain; the Susan F. Smith Center for Women's Cancers (H.J.B., E.P.W.) and the International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology (R.D.G., M.M.R.), Dana-Farber Cancer Institute, Harvard Medical School, the Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation (R.D.G.) - all in Boston; Institut Bergonié Comprehensive Cancer Center, Université de Bordeaux, Bordeaux, France (H.R.B., M.D.); the Angeles Clinic and Research Institute, Santa Monica, CA (S.M.); Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond (C.E.G.); Mayo Clinic, Rochester, MN (M.P.G., J.N.I.); Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (V.S.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (N.E.D.); Weston Park Hospital, Sheffield, United Kingdom (R.C.); and the Department of Obstetrics and Gynecology, University Medical Center, Regensburg, Germany (S.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1803164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193457PMC
July 2018

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

Int J Radiat Oncol Biol Phys 2018 06 6;101(2):316-324. Epub 2018 Feb 6.

International Breast Cancer Study Group, Bern, Switzerland; Peter MacCallum Cancer Centre, Melbourne, Australia; St. Vincents's Hospital, University of Melbourne, Australia; Breast Cancer Trials Australia & New Zealand, University of Newcastle, Newcastle, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2018.01.105DOI Listing
June 2018

Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure.

Bone 2017 Oct 1;103:131-135. Epub 2017 Jul 1.

Department of Endocrinology, Austin Health, Melbourne, Australia; Department of Medicine, Austin Health, The University of Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2017.06.024DOI Listing
October 2017

Dual HER2 Blockade.

Breast Care (Basel) 2017 Oct 30;12(5):345-349. Epub 2017 Oct 30.

Gynecology Clinic, HELIOS Hospital Berlin Buch, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000484226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704717PMC
October 2017

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

J Clin Oncol 2017 Sep 27;35(27):3113-3122. Epub 2017 Jun 27.

Poornima Saha and Gini F. Fleming, The University of Chicago Medical Center, Chicago, IL; Meredith M. Regan, Weixiu Luo, Harold J. Burstein, and Richard D. Gelber, Dana-Farber Cancer Institute; Meredith M. Regan, Harold J. Burstein, and Richard D. Gelber, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello; Karin Ribi and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern, Switzerland; Prudence A. Francis, Peter MacCallum Cancer Center; St Vincent's Hospital; University of Melbourne, Melbourne; Josephine Stewart, Austin and Heidelberg Repatriation Medical Center, Heidelberg, Victoria; Prudence A. Francis, Josephine Stewart, and Michelle Nottage, University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, New South Wales; Michelle Nottage, Royal Brisbane Hospital, Brisbane, Queensland, Australia; Barbara A. Walley, University of Calgary; National Cancer Institute of Canada, Calgary, Alberta, Canada; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Vani Parmar, Tata Memorial Centre, Mumbai, India; Roberto Torres, Instituto Nacional del Cancer, Santiago de Chile, Chile; Meritxell Bellet, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital; Universitat Autònoma de Barcelona, Barcelona; Antonia Perelló, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Faysal Dane, Marmara University Hospital, Istanbul, Turkey; Antonio Moreira, Instituto Português de Oncologia Francisco Gentil - Centro de Lisboa, Lisbon, Portugal; Daniel Vorobiof, Sandton Oncology Centre, Johannesburg, South Africa; and Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.0946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597253PMC
September 2017

Adjuvant endocrine therapy for premenopausal women: Type and duration.

Breast 2017 Aug 29;34 Suppl 1:S108-S111. Epub 2017 Jun 29.

Peter MacCallum Cancer Centre, Melbourne, Australia; St Vincents's Hospital, University of Melbourne, Australia; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle, Australia; International Breast Cancer Study Group, Bern, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.06.040DOI Listing
August 2017

Reply to F. Tomao et al.

J Clin Oncol 2016 12 30;34(34):4189-4190. Epub 2016 Sep 30.

Karin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477822PMC
December 2016

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

J Clin Oncol 2016 07 4;34(19):2221-31. Epub 2016 Apr 4.

Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/03/31/JCO.2015.64
Web Search
http://dx.doi.org/10.1200/JCO.2015.64.3171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962708PMC
July 2016

Are SOFT and TEXT results practice changing and how?

Breast 2016 Jun 22;27:122-5. Epub 2016 Apr 22.

International Breast Cancer Study Group, Bern, Switzerland; Peter MacCallum Cancer Centre, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Australia; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2016.02.008DOI Listing
June 2016

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

J Clin Oncol 2016 05 4;34(14):1584-93. Epub 2016 Jan 4.

Meritxell Bellet and Analía Azaro, Vall d'Hebron Institute of Oncology; Meritxell Bellet, Roser Ferrer, Roberto Catalán, and Analía Azaro, Vall d'Hebron University Hospital; Meritxell Bellet, Universitat Autònoma de Barcelona; Meritxell Bellet, Eva Ciruelos, Ana Lluch, Miguel Angel Climent, Gustavo Catalán, Antoni Avella, Uriel Bohn, Antonio González-Martin, Josefa Morales, and Josep Vázquez, SOLTI Group, Barcelona; Eva Ciruelos, University Hospital 12 de Octubre; Antonio González-Martin, MD Anderson Cancer Center Madrid, Madrid; Ana Lluch, Hospital Clinico Universitario de Valencia/Incliva Biomedical Research Institute; Miguel Angel Climent, Instituto Valenciano de Oncologia, Valencia; Gustavo Catalán, Hospital Son Llàtzer; Antoni Avella, Hospital Universitario Son Espases, Palma de Mallorca; Uriel Bohn, Hospital Dr Negrín de Gran Canaria, Canary Islands, Spain; Kathryn P. Gray and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray, Harvard T.H. Chan School of Public Health; Kathryn P. Gray, Karen N. Price, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Karen N. Price, Frontier Science and Technology Research Foundation; Meredith M. Regan, Harvard Medical School, Boston, MA; Agnita Rajasekaran, inVentiv Health Clinical Laboratory, Princeton, NJ; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, and International Breast Cancer Study Group, Melbourne, Victoria, Australia; and István Láng, National Institute of Oncology and International Breast Cancer Study Group, Budapest, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.2259DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872316PMC
May 2016

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

J Clin Oncol 2016 05 28;34(14):1601-10. Epub 2016 Mar 28.

Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Brea

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8675DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872319PMC
May 2016

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

N Engl J Med 2015 Mar;372(10):923-32

From the Cleveland Clinic Foundation, Cleveland (H.C.F.M.); SWOG Cancer Research Group Statistical Center, Fred Hutchinson Cancer Research Center (J.M.U., W.E.B.), and Seattle Cancer Care Alliance and University of Washington (J.G.) - all in Seattle; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC (K.-A.P., P.A.F.), Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) (K.-A.P., P.A.F., J.F.F.), Calvary Mater Hospital, Newcastle, NSW (F.B., J.M.L., J.F.F.), and University of Sydney, Sydney (F.B.) - all in Australia; International Breast Cancer Study Group (IBCSG), Bern, Switzerland (K.-A.P., P.A.F.); National Institute of Oncology, Budapest, Hungary (E.H.); Auckland Regional Cancer and Blood Service, Auckland, New Zealand (D.P.); Fox Chase Cancer Center, Philadelphia (L.J.G.); Instituto de Enfermedades Neoplasicas (H.L.G.) and Oncosalud SAC (C.S.V.), Lima, Peru; Dana-Farber Cancer Institute (A.H.P., R.D.G.) and IBCSG Statistical Center (R.D.G.) - both in Boston; Wichita Community Clinical Oncology Program, Wichita (S.R.D.), and University of Kansas, Westwood (C.J.F.) - both in Kansas; University of Southern California Norris Cancer Center, Los Angeles (A.A.G.), the Angeles Clinic and Research Institute, Santa Monica (S.M.), and University of California at Irvine Chao Family Comprehensive Cancer Center, Orange (F.L.M) - all in California; National Cancer Institute, Division of Cancer Prevention, Bethesda, MD (L.M.); M.D. Anderson Cancer Center, Houston (G.N.H.); and Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL (K.S.A.).

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/obgynsurvey/2015/06000/Gosereli
Web Search
http://www.nejm.org/doi/abs/10.1056/NEJMoa1413204
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1413204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405231PMC
March 2015

Words matter: distinguishing "personalized medicine" and "biologically personalized therapeutics".

J Natl Cancer Inst 2014 Dec 7;106(12). Epub 2014 Oct 7.

Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel (NIC); Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (EGEdV); Kellog School of Management and Northwestern University Medical School, Chicago, IL (LE); Sussex Health Outcomes Research & Education in Cancer (SHORE-C),Brighton & Sussex Medical School, University of Sussex, Falmer, UK (LF); Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (PAF); Department of Oncology, Shaare Zedek Medical Center, and Hebrew University-School of Medicine, Jerusalem, Israel (AG); Université Libre de Bruxelles, Jules Bordet Institute, Brussels, Belgium (MJP); Department of Otolaryngology and Oncology, Johns Hopkins University, Baltimore, MD (DS); Oncotest/Verify, Teva Pharmaceutical Industries, Petach Tikva, Israel (LS-G); Melabev Community Elders Care Research Department, Jerusalem, Israel (CT).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568994PMC
December 2014

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

Breast 2013 Dec 2;22(6):1094-100. Epub 2013 Oct 2.

International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.08.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855346PMC
December 2013

Strategies for the discovery and development of therapies for metastatic breast cancer.

Nat Rev Drug Discov 2012 Jun 1;11(6):479-97. Epub 2012 Jun 1.

Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd2372DOI Listing
June 2012

Optimal adjuvant therapy for very young breast cancer patients.

Breast 2011 Aug 24;20(4):297-302. Epub 2011 May 24.

Peter MacCallum Cancer Center, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2011.05.002DOI Listing
August 2011

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.

Breast 2011 Apr 24;20(2):111-8. Epub 2010 Dec 24.

Andrew Love Cancer Centre, Geelong, VIC 3220, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2010.11.003DOI Listing
April 2011

Surprised by hope.

J Clin Oncol 2008 Dec 17;26(36):6001-2. Epub 2008 Nov 17.

Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag #1, A'Beckett St, Melbourne 8006, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.0454DOI Listing
December 2008

Ovarian cancer: patterns of care in Victoria during 1993-1995.

Med J Aust 2002 Jul;177(1):11-6

Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
July 2002